Bristol-Myers Squibb Company (BMY) Showing Signs Of Being A Momo Momentum Stock.Mar 09, 2016
Bristol-Myers to Stop Paying Speaker Fees to Doctors in China.Mar 08, 2016
Drugmaker Wins Big in Japan As Its Gamble Leads To $150,000 Drug.Mar 03, 2016
Drugs Stocks On The Rise With Help From 3 Stocks.Feb 29, 2016
3 Drugs Stocks Dragging The Industry Down.Feb 18, 2016
Analysts' Actions -- Bristol-Myers, Chipotle, Monster Beverage, Vertex Pharmaceuticals and More.Feb 01, 2016
Bristol-Myers Squibb (BMY) Earnings Report: Q4 2015 Conference Call Transcript.Jan 29, 2016
Stocks Back Near Highs in Unsettled Session.Jan 28, 2016
Stocks Back to Positive as Energy Trumps Health Care.Jan 28, 2016
- Load More News...
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Unusual Social Activity Stock.Jan 28, 2016
Complete Profile Description of Bristol-Myers Squibb Co
Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
RealPennies is not a registered investment advisor, quotes are delayed.
We track all penny stocks in the OTC, OTCBB & PinkSheet Markets.